<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541889</url>
  </required_header>
  <id_info>
    <org_study_id>OU-SCC-REVEAL</org_study_id>
    <nct_id>NCT03541889</nct_id>
  </id_info>
  <brief_title>REVEAL Biomarkers of Engraftment After Alternative Donor HSCT</brief_title>
  <official_title>Multi-institutional Prospective Pilot Research of Imaging and Blood Biomarker EValuation of Engraftment After ALlogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find new tests that could help determine if the newly infused&#xD;
      bone marrow cells are growing well after bone marrow transplantation or if new bone marrow&#xD;
      cells are needed. In this study we will use FLT imaging which is an investigational imaging&#xD;
      test, and collect blood samples to investigate if the cells are growing well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective pilot study whose primary aim is to determine whether investigational&#xD;
      FLT imaging can detect and distinguish non-engraftment from delayed engraftment after&#xD;
      hematopoietic stem cell transplantation (HSCT) in populations at highest risk for graft&#xD;
      failure. The investigators will enroll 50 patients undergoing myeloblative transplantation on&#xD;
      this trial (15 pediatric and adult recipients of cord blood stem cells, 15 pediatric and&#xD;
      adult recipients of haplo-identical HSCT, and 20 recipients of these two stem cell sources&#xD;
      who have not engrafted by day 28). The planned length of this trial is 5 years and it will be&#xD;
      conducted at 3 centers: Emory/Children's Healthcare of Atlanta (pediatric and adult),&#xD;
      University of Oklahoma (adult), and University of Michigan (pediatric and adult).&#xD;
&#xD;
      For all pediatric and adult patients undergoing cord blood HSCT, three FLT images will be&#xD;
      taken: first, one day prior to HSCT and second and third, on days 9 and 28 after HSCT. For&#xD;
      recipients of haplo-HSCT, the FLT images will be taken one day prior to HSCT and then on days&#xD;
      5 and 28 after HSCT. Pediatric and adult patients who have not engrafted by day 24 after cord&#xD;
      or haplo-identical HSCT will undergo a single FLT PET/CT image within one week, to determine&#xD;
      if this scan can identify graft failure versus delayed engraftment. Blood samples will also&#xD;
      be collected from all patients for blood biomarker analysis, including thymidine kinase-1&#xD;
      (TK1). Each patient will be in this study for one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FLT SUV identifies graft failure</measure>
    <time_frame>24-28 days</time_frame>
    <description>To calculate if SUV &gt; 1.2 identifies subclinical engraftment using FLT PET/CT imaging for recipients of cord and haplo-HSCT who have not engrafted within 24 days of HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Map subclinical engraftment in alternative donor HSCT</measure>
    <time_frame>Day -1 to Day 28 after HSCT</time_frame>
    <description>Use SUV increase in particular medullary spaces to identify the first site of marrow settling after HSCT in alternative donor HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TK1 serum levels identify graft failure</measure>
    <time_frame>24-28 days</time_frame>
    <description>Calculate if TK1 level increases correlate with clinical engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CTCAE version 5 events exceeding grade 3 that are possibly, probably, or definitely attributed to the FLT imaging</measure>
    <time_frame>Day -1 to Day 28 after HSCT</time_frame>
    <description>Safety of FLT in alternative donor HSCT - Calculate the number of patients with CTCAE version 5 events exceeding grade 3 that are possibly, probably, or definitely attributed to the FLT imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other cytokine and chemokine markers of graft failure</measure>
    <time_frame>24-28 days</time_frame>
    <description>Explore other cellular, cytokine, and chemokine markers of subclinical engraftment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Graft Failure</condition>
  <arm_group>
    <arm_group_label>Cord and haplo imaging cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonengrafted cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLT imaging and TK1 blood measurements</intervention_name>
    <description>F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.</description>
    <arm_group_label>Cord and haplo imaging cohort</arm_group_label>
    <arm_group_label>Nonengrafted cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Ability to undergo 18F FLT imaging without sedation&#xD;
&#xD;
          -  Patients &gt; 4 years of age and less than 70 years of age at highest risk for graft&#xD;
             failure: cord blood HSCT, haplo HSCT, or lack of engraftment by day 28.&#xD;
&#xD;
          -  Diagnosed with a condition for which hematopoietic stem cell transplant (HSCT) is&#xD;
             standard of care and HSCT is planned (Arm A) or occurred (Arm B)&#xD;
&#xD;
          -  Able to perform FLT imaging without anesthesia&#xD;
&#xD;
          -  In morphologic remission prior to HSCT&#xD;
&#xD;
          -  Patient or guardian able to give informed consent&#xD;
&#xD;
          -  No investigational therapies within past 28 days Karnofsky or Lansky performance&#xD;
             status &gt; 60%&#xD;
&#xD;
        Arm A&#xD;
&#xD;
          -  Cord blood recipients: Absence of donor specific antibodies to cord HLA&#xD;
&#xD;
          -  Haplo-identical recipients: &gt; 5/10 and &lt; 7/8 allele mismatch donor&#xD;
&#xD;
          -  Diagnosed with a condition for which myeloablative hematopoietic stem cell transplant&#xD;
             (HSCT) is standard of care and HSCT is planned&#xD;
&#xD;
          -  Total bilirubin &lt; 2.5 mg/dL (unless documented Gilbert's syndrome) and transaminases&#xD;
             (ALT and AST) &lt; 5 x the upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance or GFR &gt; 60 ml/min/1.73 m2. (performed pre-HSCT)&#xD;
&#xD;
          -  FEV1 &gt; 80% pre or post-bronchiolator whichever is higher and DLCO Adj &gt; 70% (performed&#xD;
             pre-HSCT if age appropriate) and Sa02 &gt; 94% on room air&#xD;
&#xD;
          -  Ejection fraction &gt; 50% (performed pre-HSCT)&#xD;
&#xD;
        Arm B&#xD;
&#xD;
        â€¢ Non-engraftment recipients of cord or &gt; 5/10 and &lt; 7/8 allele mismatch donor transplant&#xD;
        (related or unrelated): primary graft failure as defined by ANC not &gt; 500 for 3 consecutive&#xD;
        days and at least 24 days after HSCT.&#xD;
&#xD;
        Inclusion Criteria - Donors&#xD;
&#xD;
          -  2 cords and &gt;.4/6 match to recipient for each (as per current National Marrow Donor&#xD;
             guidelines), with a dose &gt;2 x 10e6 CD34 cells/kg for each cord OR &gt; 5/10 and &lt;7/8&#xD;
             allele mismatch related donor&#xD;
&#xD;
          -  Institutional guidelines met for donor suitability&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of psychiatric disorder which may compromise compliance with transplant&#xD;
             protocol, or which does not allow for appropriate informed consent&#xD;
&#xD;
          -  Clinically significant systemic illness with manifestations of significant organ&#xD;
             dysfunction which, in the judgment of the PI, or Co-I, would render the patient&#xD;
             unlikely to tolerate the protocol therapy or complete the study&#xD;
&#xD;
          -  Presence of active malignancy from an organ system other than hematopoietic&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Patients who are unable or unwilling to use effective form (s) of contraception during&#xD;
             the course of the study&#xD;
&#xD;
          -  Prior history of fluorothymidine allergy or intolerance&#xD;
&#xD;
          -  Decline enrolment on CIBMTR research protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten M Williams, MD</last_name>
    <phone>404-727-4253</phone>
    <email>kirsten.marie.williams@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Holter, MD</last_name>
    <email>Jennifer-Holter@ouhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten M Williams, MD</last_name>
      <email>kirsten.marie.williams@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Kirsten M Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory A Yanick, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gregory A Yanick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Holter, MD</last_name>
      <phone>405-271-8777</phone>
      <email>Jennifer-Holter@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>IIT Office</last_name>
      <email>SCC-IIT-Office@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Holter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

